hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06319027 id: EAF223 id: NCI-2023-08557 type: REGISTRY domain: CTRP (Clinical Trial Reporting Program) id: EAF223 type: OTHER domain: ECOG-ACRIN Cancer Research Group id: EAF223 type: OTHER domain: CTEP id: U10CA180820 type: NIH link: https://reporter.nih.gov/quickSearch/U10CA180820 briefTitle: Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial overallStatus: NOT_YET_RECRUITING date: 2024-04-12 date: 2027-05-31 date: 2027-05-31 date: 2024-03-19 date: 2024-03-19 name: ECOG-ACRIN Cancer Research Group class: NETWORK briefSummary: This phase II trial studies whether different imaging techniques can provide additional and more accurate information than the usual approach for assessing the activity of tumors in patients with newly diagnosed glioblastoma. The usual approach for this currently is magnetic resonance imaging (MRI). This study is trying to learn more about the meaning of changes in MRI scans after treatment, as while the appearance of some of these changes may reflect progressing tumor, some may be due the treatment. Dynamic susceptibility contrast (DSC)-MRIs, along with positron emission tomography (PET) and/or magnetic resonance (MR) spectroscopy, may help doctors tell which changes are a reflection of the treatment and which changes may be due to progressing tumor. conditions: Glioblastoma, IDH-Wildtype studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 100 type: ESTIMATED name: Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging name: Fluciclovine F18 name: Gadolinium-Chelate name: Magnetic Resonance Spectroscopy name: Positron Emission Tomography measure: Overall survival (OS) measure: Event free survival (EFS) measure: True disease progression and pseudo-progression (PsP) measure: Progression-free survival (PFS) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06319014 id: 23-001568 briefTitle: Physical Activity to Mitigate PreEclampsia Risk acronym: PAMPER overallStatus: NOT_YET_RECRUITING date: 2024-03-31 date: 2026-04-01 date: 2026-10-01 date: 2024-03-19 date: 2024-03-19 name: East Carolina University class: OTHER briefSummary: The purpose of this study is to compare the effects of aerobic (AE), resistance (RE), and combination (AERE) exercise throughout pregnancy on selected maternal and fetal/neonatal physiological variables in women at-risk for preeclampsia. The central hypothesis of this project is that exercise will decrease severity and occurrence of preeclampsia symptoms, thus improving maternal, pregnancy, and birth outcomes.
nctId: NCT06319001 id: 2688791 briefTitle: Cardiovascular Reactivity to Physical Stress acronym: REACT overallStatus: RECRUITING date: 2024-02-19 date: 2027-01-01 date: 2027-01-01 date: 2024-03-19 date: 2024-03-19 name: Western Norway University of Applied Sciences class: OTHER briefSummary: It is well-accepted that an exaggerated blood pressure (BP) response to physical stress has a prognostic value, indicating a higher cardiovascular risk (e.g., sudden cardiac death, myocardial infarction, future hypertension, and left ventricular hypertrophy). However, there is a limited understanding of the underlying mechanisms and therapuetic strategies modulating this response. Therefore, this pilot project aims to explore whether one session of low-volume high-intensity interval training (low-volume HIIT) or combined intermittent heat and cold bath (sauna+cold bath) can decrease BP responses to physical stress. Furthermore, the secondary goal is to investigate whether one brief session learning about positive stress expectations magnifies the decrease in BP following low-volume HIIT and sauna+ cold bath. conditions: Blood Pressure conditions: Stress, Physiological studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Combined randomized controlled trial with two parallel groups primaryPurpose: OTHER masking: NONE count: 58 type: ESTIMATED name: Low-volume high intensity exercise name: Combined intermittent sauna and cold water bath (sauna+cold bath). measure: Blood pressure (unit: mmHg) response to laboratory stressors measure: Resting blood pressure (mmHg). measure: Endothelial function (% dilation) measure: Subjective ratings of expectancies (point score). sex: ALL minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT facility: Western Norway University of Applied Sciences status: RECRUITING city: Bergen state: Vestland zip: 5063 country: Norway name: Ann-Katrin Grotle role: CONTACT phone: +4790960580 email: ann-katrin.grotle@hvl.no lat: 60.39299 lon: 5.32415 hasResults: False
nctId: NCT06318988 id: S67030 briefTitle: Outcomes of Different Treatment Options in Chronic Venous Disease acronym: VOS overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2026-11-01 date: 2027-05-01 date: 2024-03-19 date: 2024-03-19 name: Universitaire Ziekenhuizen KU Leuven class: OTHER briefSummary: This study aims to describe conservative and invasive treatments for patients with chronic venous disease (CVD) in Belgium, and their association with clinical and patient-reported outcomes during a follow-up of 24 months. conditions: Chronic Venous Disease studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 2000 type: ESTIMATED name: Radiofrequency ablation using Closure fast name: Aethoxysclerol name: Daflon name: Compression stocking measure: Change in Chronic Venous Insufficiency QOL questionnaire- 20 (CIVIQ-20) score measure: Intervention as secondary/add-on treatment measure: The change in the Chronic Venous Insufficiency QOL questionnaire-20 score (CIVIQ-20) measure: The change in the clinical part of the Clinical, Etiological, Anatomical and Pathophysiological classification (CEAP classification) measure: The change in the revised Venous Clinical Severity Score (rVCSS) measure: The change in the symptoms, recorded with a questionnaire measure: The change in satisfaction score measure: Adverse Events (AEs). sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06318975 id: RAPTOR id: R01AA029074 type: NIH link: https://reporter.nih.gov/quickSearch/R01AA029074 briefTitle: Text-Based Messaging Strategies for Preventing Subsequent Problematic Alcohol Use overallStatus: RECRUITING date: 2023-12-01 date: 2027-12-31 date: 2028-12-31 date: 2024-03-19 date: 2024-03-19 name: University of Virginia class: OTHER name: University of Memphis name: National Institute on Alcohol Abuse and Alcoholism (NIAAA) briefSummary: Binge drinking, and its health/social consequences are substantial public health concerns, with a high prevalence in young adults, especially in the US military. Alcohol consumption in the military is very high and normative, but there is zero tolerance for alcohol-related legal trouble, and Air Force Airmen who experience this (e.g., DUI, sexual assault) typically receive a disciplinary action referred to as an Alcohol Related Incident (ARI).
Brief Alcohol Interventions (BAIs) for alcohol misuse are effective in young adults who report binge drinking. Many BAI studies targeted young adults who drink hazardously; these individuals are typically not interested in abstaining but may try decreasing the amount or change the manner in which they drink in order to reduce harmful consequences. The investigators previously published the results of a BAI group-based intervention that reduced ARIs in over 150,000 Airmen on average by 16%. Since 2010, the BAI has been disseminated to most USAF Airmen in Technical Training. However, it is clear additional research is needed to enhance the efficacy of the intervention and reduce risks associated with problem drinking. One strategy to improve health outcomes is well-timed, tailored, and automated text messages. Building on the researchers' preliminary study where text messages reduced driving after drinking as well as total drinks consumed before driving, text messaging may be highly effective when sent at the precise time that Airmen gain access to alcohol (the first time they are allowed off base), a standard time for all Technical Trainees.
One challenge to conducting alcohol research in the military is the lack of privileged communication. As a result, it is difficult to obtain valid self-reports due to a tendency to deny or minimize use. The investigators recently developed and validated a method for collecting anonymous data over time. This will be the first study in the military, as well as the first large scale, adequately powered trial, where intervention effects will be tracked out to a 6-month follow-up. The study's Specific Aims are to randomize approximately 3000 Airmen to either the current BAI versus the BAI+Text messages timed to occur before, during, and after Airmen have access to alcohol; and to evaluate the efficacy of the intervention at the end of training and 6 months post-training using repeated surveys with unique identifiers allowing researchers to match surveys while maintaining anonymity. conditions: Alcohol Drinking conditions: Binge Drinking conditions: Text Messaging studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: NONE count: 3000 type: ESTIMATED name: Brief Alcohol Intervention name: Automated and Tailored Text Messages measure: AUDIT measure: Daily Drinking Questionnaire with NIAAA recommended assessment items sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: JBSA Lackland status: RECRUITING city: San Antonio state: Texas zip: 78236 country: United States name: Tina Boothe, MPH role: CONTACT email: tlb7aq@virginia.edu lat: 29.42412 lon: -98.49363 typeAbbrev: ICF hasProtocol: False hasSap: False hasIcf: True label: Informed Consent Form date: 2023-09-25 uploadDate: 2024-02-28T11:41 filename: ICF_000.pdf size: 160063 hasResults: False
nctId: NCT06318949 id: 87RI22_0007 (MALAHBAR) briefTitle: Albumin Modifications as Early Biomarkers of Chronic Liver Diseases acronym: MALAHBAR overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2029-06-01 date: 2029-12-01 date: 2024-03-19 date: 2024-03-19 name: University Hospital, Limoges class: OTHER briefSummary: Chronic liver diseases, affecting over 800 million people worldwide, lead to approximately 2 million annual deaths. The need for early, sensitive diagnostic strategies to prevent disease progression and reduce mortality is still unmet. The traditional serum markers lack sensitivity and specificity, leading to the integration of these biomarkers into panel tests with algorithms or imaging measures. Despite their widespread use, these tests have limitations at an individual level, including an inability to predict disease progression or response to treatment. To address these shortcomings, our project proposes utilizing albumin post-translational modifications (PTM) as a predictive biomarker for liver disease progression. The hypothesis is that albumin modifications occur in the early stages of hepatocellular damage and are indicative of future liver diseases. These modifications can be detected through serum albumin isoform determination, albumin isoforms profiles or the albumin's ligand-binding capacities. Innovatively, the study will use the Serum Enhanced Binding (SEB) test, which identifies reduced ligand-binding capacities, and discusses a second patent for determining a typical isoform profile based on the hepatic injury type.
nctId: NCT06318936 id: 22-677 briefTitle: Respiratory Syncytial Virus (RSV) Burden in Older Adults in Primary Care in The Netherlands acronym: RAPID overallStatus: RECRUITING date: 2022-11-01 date: 2024-05-01 date: 2024-05-01 date: 2024-03-19 date: 2024-03-19 name: UMC Utrecht class: OTHER name: Janssen-Cilag B.V. briefSummary: RSV infection is a leading cause of medical care in older adults, sometimes leading to hospital admission and severe outcomes. Although the majority of RSV infections are managed outside hospitals, little is known on the burden of RSV in older adults in the primary care setting. Accurate estimates of the RSV burden in primary care is particularly relevant since vaccines against RSV infection in older adults will likely become available for the general population soon. The use of high-quality point-of-care (POC) molecular viral diagnostics allows to identify RSV infected older adults and would therefore contribute to fill one of the most important gaps in knowledge facilitating implementation of RSV vaccination of older adults
With this prospective, observational study, we aim to define the disease burden of RSV infection in older adults in the primary care setting. conditions: RSV Infection studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 100 type: ESTIMATED measure: Burden of medically attended RSV infection in the Dutch primary care measure: RSV-related health care consumption and indirect costs in older adults measure: Proportion of medically attended RSV infection amongst all medically attended acute respiratory infections in older adults in the primary care setting measure: Association between disease severity and several clinical and demographic parameters (e.g. age, cardiopulmonary comorbidity, smoking status, chronic immunosuppressive medication use) and RSV burden (by disease severity and healthcare usage) measure: Incidence of RSV-related secondary bacterial pneumonia events and antibiotic use sex: ALL minimumAge: 60 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University Medical Center Utrecht status: RECRUITING city: Utrecht zip: 3584CX country: Netherlands name: Joanne Wildenbeest, MD, PhD role: CONTACT phone: 0031887563776 email: J.G.Wildenbeest@umcutrecht.nl lat: 52.09083 lon: 5.12222 hasResults: False
nctId: NCT06318923 id: RC-P00117 briefTitle: Social and Moral Cognition in Multiple Sclerosis acronym: COSMOS overallStatus: RECRUITING date: 2023-12-19 date: 2025-04-30 date: 2025-10-30 date: 2024-03-19 date: 2024-03-20 name: Lille Catholic University class: OTHER briefSummary: Multiple Sclerosis (MS) is a chronic, progressive disease that affects young adults (aged between 20 and 40) and has a major impact on patients' quality of life. Cognitive disorders in MS are common, affecting 40-60% of patients. Among these disorders, the presence of social cognition disorders is common. Within social cognition, the moral judgment has been an object of research in order to understand the determinants of moral decision-making: how and why individuals make moral choices with regard to a set of prescriptions and social norms. Compared to control subjects, MS patients show a decrease in moral permissiveness, as well as an increase in moral relativity and emotional reactivity. Thus, it would seem that MS patients issue more deontological choices (lower moral permissiveness). Given that these patients also exhibit empathy deficits and higher alexithymia, these patterns are surprising. Indeed, in other clinical populations, low empathic abilities and high alexithymia are linked to utilitarian rather than deontological moral judgments.
The objective of this project is to analyze the process of decision-making carried out by patients during moral dilemma situations in comparison with control individuals and verify whether the presence of a positivity bias could explain the more deontological choices made by some patients. Indeed, some work has shown that older individuals make more deontological moral judgments than younger adults. These results are also observed with young individuals when their future temporal perspectives have been experimentally constrained. conditions: Multiple Sclerosis studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: NONE count: 90 type: ESTIMATED name: Socio-demographic questionnaire, moral judgment task, cognitive tests, psychoaffective assessment name: MS questionnaire name: MONTREAL COGNITIVE ASSESSMENT (MoCA) test measure: Moral dilemma judgments measure: Explicit time perspective inventory test measure: Implicit time perspective inventory test measure: Dot Probe Task measure: Level of moral permissibility measure: Level of emotional reactivity measure: Moral relativity level measure: Brief International Cognitive Assessment for Multiple Sclerosis measure: The Beck Depression Inventory measure: State-Trait Anxiety Inventory measure: Toronto Alexithymia Scale (TAS)-20 measure: Empathy quotient-8 (EQ-8) measure: Electrodermal response sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT facility: Hôpital Saint-Vincent-de-Paul - Neurologie status: RECRUITING city: Lille country: France name: Béatrice DEGRAEVE role: CONTACT name: Laurent ZIKOS role: SUB_INVESTIGATOR lat: 50.63297 lon: 3.05858 facility: Hôpital Saint-Philibert - Neurologie status: RECRUITING city: Lomme country: France name: Béatrice DEGRAEVE role: CONTACT name: Laurent ZIKOS role: SUB_INVESTIGATOR lat: 50.64358 lon: 2.98715 hasResults: False
nctId: NCT06318910 id: MU-SRF-RS-27 C/66 briefTitle: Customized Foot Orthoses on Muscle Activity During Standing and Gait in Plantar Heel Pain overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2024-11-30 date: 2024-12-31 date: 2024-03-19 date: 2024-03-19 name: Mahidol University class: OTHER briefSummary: The present study will use a randomized controlled trial (RCT) to determine the effectiveness of customized foot orthosis (CFO) for the treatment of patients with PHP. Three treatment groups including the CFO without wedge, the CFO with wedge type 1 (W1), and the CFO with wedge type 2 (W2) will be randomly assigned to each participant by a computer-generated randomization. The opaque-sealed envelopes will be used to allocate the groups of participant. conditions: Foot Orthoses conditions: Fasciitis, Plantar studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: SINGLE_GROUP interventionModelDescription: The present study will use a randomized controlled trial (RCT) to determine the effectiveness of CFO for the treatment of patients with PHP. Three treatment groups including the CFO without wedge, the CFO with W1, and the CFO with W2 will be randomly assigned to each participant by a computer-generated randomization. The opaque-sealed envelopes will be used to allocate the groups of participant. primaryPurpose: TREATMENT masking: SINGLE maskingDescription: Participants will be allocated to the control (CFO without wedge) or experimental (CFO with W1 or W2) groups according to the seal-envelop randomization technique. Then, they will be assessed all outcomes for the baseline including pain intensity, foot function, lower-extremity muscle activity during gait and standing by the 2nd physical therapist. And the participants will receive the assigned treatment by the 1st physical therapist. whoMasked: OUTCOMES_ASSESSOR count: 75 type: ESTIMATED name: orthotic wedge name: CFO measure: Pain intensity and foot function measure: EMG of lower leg muscles measure: Subjective assessment measure: Physical assessment sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT hasResults: False
nctId: NCT06318897 id: 2023-0645 id: NCI-2024-02384 type: OTHER domain: NCI-CTRP Clinical Registry briefTitle: Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer overallStatus: NOT_YET_RECRUITING date: 2024-09-30 date: 2025-09-30 date: 2027-09-30 date: 2024-03-19 date: 2024-03-19 name: M.D. Anderson Cancer Center class: OTHER briefSummary: To look at the effectiveness of the combination of pembrolizumab, carboplatin, and paclitaxel in participants with stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer. conditions: Stage 1 cT1b-T1cN0M0 conditions: Triple Negative Breast Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 28 type: ESTIMATED name: Carboplatin name: Paclitaxel name: Pembrolizumab name: Doxorubicin name: Cyclophosphamide measure: Safety and adverse events (AEs) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: MD Anderson Cancer Center city: Houston state: Texas zip: 77030 country: United States name: Oluchi Oke, MD role: CONTACT phone: 832-729-8362 email: oukaegbu@mdanderson.org name: Oluchi Oke, MD role: PRINCIPAL_INVESTIGATOR lat: 29.76328 lon: -95.36327 hasResults: False
nctId: NCT06318884 id: SCTB35-X101 briefTitle: A First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin Lymphoma overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2026-10 date: 2027-12 date: 2024-03-19 date: 2024-03-22 name: Sinocelltech Ltd. class: INDUSTRY briefSummary: This is a Phase I clinical study designed to evaluate the safety, tolerability, and pharmacokinetics, and preliminary efficacy of SCTB35 monotherapy, an bispecific antibody, in patients with relapsed and/or refractory B-cell non-Hodgkin lymphoma. conditions: Non-Hodgkin Lymphoma, B-cell studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 76 type: ESTIMATED name: SCTB35 injection measure: Dose-escalation part: dose limited toxicity (DLT) measure: Dose-escalation part: incidence rate of adverse event (AE) measure: Dose-expansion part: objective response rate (ORR) measure: Dose-escalation part: ORR measure: Dose-escalation part: CR rate (CRR) measure: Dose-escalation part: best of overall response (BOR) measure: Dose-escalation part: duration of response (DOR) measure: Dose-escalation part: progression-free survival (PFS) measure: Dose-escalation part: time to response (TTR) measure: Dose-escalation part: overall survival (OS) measure: Dose-escalation part: blood concentrations of SCTB35 measure: Dose-escalation part: anti-drug antibodies of SCTB35 measure: Dose-expansion part: CRR measure: Dose-expansion part: BOR measure: Dose-expansion part: DOR measure: Dose-expansion part: PFS measure: Dose-expansion part: TTR measure: Dose-expansion part: OS measure: Dose-expansion part: AE measure: Dose-expansion part: blood concentrations of SCTB35 measure: Dose-expansion part: anti-drug antibodies of SCTB35 sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Beijing Cancer Hospital city: Beijing state: Beijing zip: 100142 country: China name: Yuqin Song, M.D. role: CONTACT phone: 010-88196118 email: SongYQ_VIP@163.com lat: 39.9075 lon: 116.39723 facility: Henan Cancer Hospital city: Zhengzhou state: Henan country: China name: Keshu Zhou, M.D. role: CONTACT phone: 13674902391 email: dr_zkshu23810@163.com lat: 34.75778 lon: 113.64861 facility: Tianjin Medical University Cancer Institute & Hospital city: Tianjin state: Tianjin zip: 300060 country: China name: Lanfang Li, M.D. role: CONTACT phone: 18622221613 email: lilanfangmeng@163.com lat: 39.14222 lon: 117.17667 hasResults: False
nctId: NCT06318871 id: 23-688 briefTitle: A Phase 0 Pilot Study of Memory-like Natural Killer (NK) Cell Immune Therapy in Combination With N-803 in Patients With Renal Cell Carcinoma or Urothelial Carcinoma overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-02-28 date: 2030-02-28 date: 2024-03-19 date: 2024-03-19 name: Dana-Farber Cancer Institute class: OTHER name: Kidney Cancer Association name: ImmunityBio, Inc. briefSummary: The goal of this research study is to establish the safety and then to explore the effectiveness of infusing the combination of cytokine-induced memory-like (CIML) natural killer (NK) cells, a type of immune cell in the blood that is collected and bathed in special proteins to help identify and treat curtained advanced cancers, combined with N-803, a medication that increases the activity of Interleukin-15, which is a cytokine that activates immune cells, in advanced clear cell renal cell carcinoma and urothelial carcinoma.